Publications by authors named "Seyyid Baloglu"

9 Publications

  • Page 1 of 1

Endoscopic Transorbital Approaches to Anterior and Middle Cranial Fossa: Exploring the Potentialities of a Modified Lateral Retrocanthal Approach.

Authors:
Salvatore Chibbaro Mario Ganau Antonino Scibilia Julien Todeschi Ismail Zaed Maria Teresa Bozzi Irène Ollivier Hélène Cebula Marie des Neiges Santin Idir Djennaoui Christian Debry Pierre Mahoudau Paolo Di Emidio Stephane Kraemer Seyyid Baloglu Francois Proust Beniamino Alessandro Nannavecchia

World Neurosurg 2021 Feb 27. Epub 2021 Feb 27.

Department of Neurosurgery, Strasbourg University Hospital, Strasbourg, France.

Background: Among the new perspectives to revolutionize skull base surgery, there are the transorbital neuroendoscopic (TONES) approaches to reach the anterior and middle cranial fossa (ACF and MCF). We conceived to explore the potentialities of a modified superiorly and medially extended lateral retrocanthal (LRC) approach.

Methods: Six head specimens were dissected. Applying the established conic model and the key surgical landmark of sphenofrontal suture, we tested the feasibility of a modified LRC to reach ACF and MCF; computed tomography (CT) scans were performed before and after dissection to obtain a morphometric analysis of the surgical corridors using a polygonal surfaces model.

Results: Through our anatomical study, we were able to identify and explore 3 different surgical corridors to reach the ACF and MCF: the superomedial, the superolateral, and the inferolateral. The superomedial corridor appeared most suitable to reach the medial part of the ACF and the optic-carotid region, whereas through the superolateral and inferolateral corridors it was possible to reach and explore the lateral part of ACF and MCF. The mean volumes of the 3 surgical corridors calculated on post-dissection CT scans were: 12.72 ± 1.99, 5.69 ± 0.34, and 6.24 ± 0.47 cm, respectively.

Conclusions: The development of TONES approaches has not replaced the traditional open or endoscopic approach; nonetheless, identification of surgical corridors and the possibility to combine them represent a major breakthrough. Clinical studies are necessary to demonstrate their validity and test the effectiveness, safety, and reproducibility of TONES approaches in managing lesions harboring in the ACF and MCF.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.wneu.2021.02.095DOI Listing
February 2021

Association of cerebral microbleeds with cerebrospinal fluid Alzheimer-biomarkers and clinical symptoms in early dementia with Lewy bodies.

Authors:
Aline Mendes Vincent Noblet Mary Mondino Paulo Loureiro de Sousa Sumayya Manji Anne Archenault Michel Casanovas Olivier Bousiges Nathalie Philippi Seyyid Baloglu Lucie Rauch Benjamin Cretin Catherine Demuynck Catherine Martin-Hunyadi Frederic Blanc

Int J Geriatr Psychiatry 2020 Dec 9. Epub 2020 Dec 9.

IMIS Team and IRIS Plateform, ICube Laboratory, UMR 7357, French National Centre for Scientific Research (CNRS), Strasbourg, France.

Objectives: To determine the prevalence, localization and associations of cerebral microbleeds (CMB) in dementia with Lewy bodies (DLB) with its core clinical symptoms and cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD). We hypothesize DLB patients with CMB have increased amyloid burden compared to those without CMB, which could also translate into clinical differences.

Methods: Retrospective cross-sectional analysis from the AlphaLewyMA study (https://clinicaltrials.gov/ct2/show/NCT01876459). Patients underwent a standardized protocol of brain MRI including 3D T1, 3D FLAIR and T2* sequences, and CSF analysis of AD biomarkers. CMB and white matter hyperintensities (WMHs) were visually assessed in prodromal and mild demented (DLB, N = 91) and AD (AD, N = 67) patients.

Results: CMB prevalence did not differ among DLB and AD (24.2% vs. 37.3%; p = 0.081). CMB were mainly distributed in lobar topographies in both DLB (74%) and AD (89%). CMB in DLB was not associated with global cognitive performance, executive functioning, speed of information processing, or AD CSF biomarkers. Similarly, there was no difference regarding specific clinical symptoms: fluctuations, psychotic phenomena, sleep behavior disorder and Parkinsonism between DLB patients with and without CMB. AD patients with CMB had increased burden of WMH compared to those without (2.1 ± 0.86 vs. 1.4 ± 0.89; p = 0.005), according to Fazekas scale, whereas no significant difference was observed in DLB patients (1.68 ± 0.95 vs. 1.42 ± 0.91; p = 0.25).

Conclusion: CMB were equally prevalent with similar topographic distribution in both DLB and AD patients. CMB was not associated with CSF AD biomarkers or core clinical symptoms in DLB.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1002/gps.5485DOI Listing
December 2020

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.

Authors:
Manel Alleg Morgane Solis Seyyid Baloglu François Cotton Philippe Kerschen Bertrand Bourre Guido Ahle Jean-Pierre Pruvo Xavier Leclerc Patrick Vermersch Caroline Papeix Élisabeth Maillart Caroline Houillier Cécile Moluçon Chabrot Béatrice Claise Sandra Malak Guillaume Martin-Blondel Fabrice Bonneville Alexis Caulier Jean-Pierre Marolleau Jérôme Tamburini Bonnefoy Philippe Agape Céline Kennel Xavier Roussel Adrien Chauchet Jérôme De Seze Samira Fafi-Kremer Stéphane Kremer

Eur Radiol 2021 May 6;31(5):2944-2955. Epub 2020 Nov 6.

Hôpitaux Universitaires de Strasbourg, Service d'imagerie 2, Hôpital de Hautepierre, Strasbourg, France.

Objectives: To compare brain MRI findings in progressive multifocal leukoencephalopathy (PML) associated to rituximab and natalizumab treatments and HIV infection.

Materials And Methods: In this retrospective, multicentric study, we analyzed brain MRI exams from 72 patients diagnosed with definite PML: 32 after natalizumab treatment, 20 after rituximab treatment, and 20 HIV patients. We compared T2- or FLAIR-weighted images, diffusion-weighted images, T2*-weighted images, and contrast enhancement features, as well as lesion distribution, especially gray matter involvement.

Results: The three PML entities affect U-fibers associated with low signal intensities on T2*-weighted sequences. Natalizumab-associated PML showed a punctuate microcystic appearance in or in the vicinity of the main PML lesions, a potential involvement of the cortex, and contrast enhancement. HIV and rituximab-associated PML showed only mild contrast enhancement, punctuate appearance, and cortical involvement. The CD4/CD8 ratio showed a trend to be higher in the natalizumab group, possibly mirroring a more efficient immune response.

Conclusion: Imaging features of rituximab-associated PML are different from those of natalizumab-associated PML and are closer to those observed in HIV-associated PML.

Key Points: • Nowadays, PML is emerging as a complication of new effective therapies based on monoclonal antibodies. • Natalizumab-associated PML shows more inflammatory signs, a perivascular distribution "the milky way," and more cortex involvement than rituximab- and HIV-associated PML. • MRI differences are probably related to higher levels of immunosuppression in HIV patients and those under rituximab therapy.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00330-020-07362-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644389PMC
May 2021

Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study.

Authors:
Stéphane Kremer François Lersy Mathieu Anheim Hamid Merdji Maleka Schenck Hélène Oesterlé Federico Bolognini Julien Messie Antoine Khalil Augustin Gaudemer Sophie Carré Manel Alleg Claire Lecocq Emmanuelle Schmitt René Anxionnat François Zhu Lavinia Jager Patrick Nesser Yannick Talla Mba Ghazi Hmeydia Joseph Benzakoun Catherine Oppenheim Jean-Christophe Ferré Adel Maamar Béatrice Carsin-Nicol Pierre-Olivier Comby Frédéric Ricolfi Pierre Thouant Claire Boutet Xavier Fabre Géraud Forestier Isaure de Beaurepaire Grégoire Bornet Hubert Desal Grégoire Boulouis Jérome Berge Apolline Kazémi Nadya Pyatigorskaya Augustin Lecler Suzana Saleme Myriam Edjlali-Goujon Basile Kerleroux Jean-Marc Constans Pierre-Emmanuel Zorn Muriel Mathieu Seyyid Baloglu François-Daniel Ardellier Thibault Willaume Jean-Christophe Brisset Sophie Caillard Olivier Collange Paul Michel Mertes Francis Schneider Samira Fafi-Kremer Mickael Ohana Ferhat Meziani Nicolas Meyer Julie Helms François Cotton

Neurology 2020 09 17;95(13):e1868-e1882. Epub 2020 Jul 17.

From the Hôpitaux Universitaires de Strasbourg (S.K., F.L., S.B., F.-D.A., T.W.), Service d'imagerie 2, Hôpital de Hautepierre; Engineering Science, Computer Science and Imaging Laboratory (S.K., N.M.), UMR 7357, University of Strasbourg-CNRS; Service de Neurologie (M. Anheim), Hôpitaux Universitaires de Strasbourg; Institut de Génétique et de Biologie Moléculaire et Cellulaire (M. Anheim), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch; Fédération de Médecine Translationnelle de Strasbourg (M. Anheim), Université de Strasbourg; Hôpitaux universitaires de Strasbourg (H.M., F.M., J.H.), Service de Médecine Intensive Réanimation, Nouvel Hôpital Civil; INSERM (French National Institute of Health and Medical Research) (H.M., F.M.), UMR 1260, Regenerative Nanomedicine, Fédération de Médecine Translationnelle de Strasbourg; Médecine Intensive-Réanimation (M.S., F.S.), Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg; Service de Neuroradiologie (H.O., F.B., J.M.), Hôpitaux Civils de Colmar; Service d'Imagerie (A. Khalil, A.G.), Unité de Neuroradiologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat Claude Bernard; Université Paris Diderot (A. Khalil), Paris; Service de Neurologie (S. Carré, C.L.), Centre Hospitalier de Haguenau; Service de Radiologie (M. Alleg), Centre Hospitalier de Haguenau; Service de Neuroradiologie, (E.S., R.A., F.Z.) Hôpital Central, CHU de Nancy; CHIC Unisanté (L.J., P.N., Y.T.M.), Hôpital Marie Madeleine, Forbach; Neuroimaging Department (G.H., J. Benzakoun, C.O., G. Boulouis, M.E.-G., B.K.), GHU Paris Psychiatrie et Neurosciences, Hôpital Sainte-Anne, Université de Paris, INSERM U1266, F-75014; CHU Rennes (J.-C.F., B.C.-N.), Department of Neuroradiology; CHU Rennes (A.M.), Medical Intensive Care Unit; Department of Neuroradiology (P.-O.C., F.R., P.T.), University Hospital of Dijon, Hôpital François Mitterrand; Service de Radiologie (C.B.), CHU de Saint-Etienne; Service de Réanimation (X.F.), CH de Roanne; Service de Neuroradiologie (G.F., S.S.), CHU de Limoges; Radiology Department (I.d.B., G. Bornet), Hôpital Privé d'Antony; Department of Diagnostic and Interventional Neuroradiology (H.D.), University Hospital, Nantes; Neuroradiology Department (J. Berge), CHU de Bordeaux; Service de Neuroradiologie (A. Kazémi), CHU de Lille; Assistance Publique Hôpitaux de Paris (N.P.), Service de Neuroradiologie, Hôpital Pitié-Salpêtrière; Sorbonne Université (N.P.), Univ Paris 06, UMR S 1127, CNRS UMR 7225, ICM, F-75013; Service de Neuroradiologie Diagnostique (A.L.), Foundation A. Rothschild Hospital, Paris; EA CHIMERE 7516 (J.-M.C.), Université de Picardie Jules Verne; Service de NeuroRadiologie, pôle Imagerie Médicale, Centre Hospitalo-Universitaire d'Amiens; Hôpitaux Universitaires de Strasbourg (P.-E.Z., M.M.), UCIEC, Pôle d'Imagerie, Strasbourg; Observatoire Français de la Sclérose en Plaques (J.-C.B.), Lyon; Nephrology and Transplantation Department (S. Caillard), Hôpitaux Universitaires de Strasbourg; Inserm UMR S1109 (S. Caillard), LabEx Transplantex, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg; Hôpitaux Universitaires de Strasbourg (O.C., P.M.M.), Service d'Anesthésie-Réanimation, Nouvel Hôpital Civil; Hôpitaux Universitaires de Strasbourg (S.F.-K.), Laboratoire de Virologie Médicale; Radiology Department (M.O.), Nouvel Hôpital Civil, Strasbourg University Hospital; CHU de Strasbourg (N.M.), Service de Santé Publique, GMRC, F-67091 Strasbourg; Immuno-Rhumatologie Moléculaire (S.F.-K., J.H.), INSERM UMR_S1109, LabEx TRANSPLANTEX, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg; MRI Center (F.C.), Centre Hospitalier Lyon Sud, Hospices Civils de Lyon; and Université Lyon 1 (F.C.), CREATIS-LRMN, CNRS/UMR/5220-INSERM U630, Villeurbanne, France.

Objective: To describe neuroimaging findings and to report the epidemiologic and clinical characteristics of patients with coronavirus disease 2019 (COVID-19) with neurologic manifestations.

Methods: In this retrospective multicenter study (11 hospitals), we included 64 patients with confirmed COVID-19 with neurologic manifestations who underwent a brain MRI.

Results: The cohort included 43 men (67%) and 21 women (33%); their median age was 66 (range 20-92) years. Thirty-six (56%) brain MRIs were considered abnormal, possibly related to severe acute respiratory syndrome coronavirus. Ischemic strokes (27%), leptomeningeal enhancement (17%), and encephalitis (13%) were the most frequent neuroimaging findings. Confusion (53%) was the most common neurologic manifestation, followed by impaired consciousness (39%), presence of clinical signs of corticospinal tract involvement (31%), agitation (31%), and headache (16%). The profile of patients experiencing ischemic stroke was different from that of other patients with abnormal brain imaging: the former less frequently had acute respiratory distress syndrome ( = 0.006) and more frequently had corticospinal tract signs ( = 0.02). Patients with encephalitis were younger ( = 0.007), whereas agitation was more frequent for patients with leptomeningeal enhancement ( = 0.009).

Conclusions: Patients with COVID-19 may develop a wide range of neurologic symptoms, which can be associated with severe and fatal complications such as ischemic stroke or encephalitis. In terms of meningoencephalitis involvement, even if a direct effect of the virus cannot be excluded, the pathophysiology seems to involve an immune or inflammatory process given the presence of signs of inflammation in both CSF and neuroimaging but the lack of virus in CSF.

Clinicaltrialsgov Identifier: NCT04368390.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1212/WNL.0000000000010112DOI Listing
September 2020

Coronavirus Disease 2019: Associated Multiple Organ Damage.

Authors:
Olivier Collange Charles Tacquard Xavier Delabranche Ian Leonard-Lorant Mickaël Ohana Mihaela Onea Mathieu Anheim Morgane Solis Arnaud Sauer Seyyid Baloglu Patrick Pessaux Patrick Ohlmann Charlotte Kaeuffer Walid Oulehri Stephane Kremer Paul Michel Mertes

Open Forum Infect Dis 2020 Jul 21;7(7):ofaa249. Epub 2020 Jun 21.

Service d'Anesthésie-Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

A 56-year-old man presented a particularly severe and multisystemic case of coronavirus disease 2019 (COVID-19). In addition to the common lung and quite common pulmonary embolism and kidney injuries, he presented ocular and intestinal injuries that, to our knowledge, have not been described in COVID-19 patients. Although it is difficult to make pathophysiological hypotheses about a single case, the multiplicity of injured organs argues for a systemic response to pulmonary infection. A better understanding of physiopathology should feed the discussion about therapeutic options in this type of multifocal damage related to severe acute respiratory syndrome coronavirus 2.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1093/ofid/ofaa249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336548PMC
July 2020

Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study.

Authors:
Stéphane Kremer François Lersy Jérome de Sèze Jean-Christophe Ferré Adel Maamar Béatrice Carsin-Nicol Olivier Collange Fabrice Bonneville Gilles Adam Guillaume Martin-Blondel Marie Rafiq Thomas Geeraerts Louis Delamarre Sylvie Grand Alexandre Krainik Sophie Caillard Jean Marc Constans Serge Metanbou Adrien Heintz Julie Helms Maleka Schenck Nicolas Lefèbvre Claire Boutet Xavier Fabre Géraud Forestier Isaure de Beaurepaire Grégoire Bornet Audrey Lacalm Hélène Oesterlé Federico Bolognini Julien Messié Ghazi Hmeydia Joseph Benzakoun Catherine Oppenheim Blanche Bapst Imen Megdiche Marie-Cécile Henry Feugeas Antoine Khalil Augustin Gaudemer Lavinia Jager Patrick Nesser Yannick Talla Mba Céline Hemmert Philippe Feuerstein Nathan Sebag Sophie Carré Manel Alleg Claire Lecocq Emmanuelle Schmitt René Anxionnat François Zhu Pierre-Olivier Comby Frédéric Ricolfi Pierre Thouant Hubert Desal Grégoire Boulouis Jérome Berge Apolline Kazémi Nadya Pyatigorskaya Augustin Lecler Suzana Saleme Myriam Edjlali-Goujon Basile Kerleroux Pierre-Emmanuel Zorn Muriel Matthieu Seyyid Baloglu François-Daniel Ardellier Thibault Willaume Jean Christophe Brisset Clotilde Boulay Véronique Mutschler Yves Hansmann Paul-Michel Mertes Francis Schneider Samira Fafi-Kremer Mickael Ohana Ferhat Meziani Jean-Stéphane David Nicolas Meyer Mathieu Anheim François Cotton

Radiology 2020 11 16;297(2):E242-E251. Epub 2020 Jun 16.

From the Hôpitaux Universitaires de Strasbourg, Service d'Imagerie 2, Hôpital de Hautepierre, Strasbourg, France (S.K.).

Background Brain MRI parenchymal signal abnormalities have been associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Purpose To describe the neuroimaging findings (excluding ischemic infarcts) in patients with severe coronavirus disease 2019 (COVID-19) infection. Materials and Methods This was a retrospective study of patients evaluated from March 23, 2020, to April 27, 2020, at 16 hospitals. Inclusion criteria were () positive nasopharyngeal or lower respiratory tract reverse transcriptase polymerase chain reaction assays, () severe COVID-19 infection defined as a requirement for hospitalization and oxygen therapy, () neurologic manifestations, and () abnormal brain MRI findings. Exclusion criteria were patients with missing or noncontributory data regarding brain MRI or brain MRI showing ischemic infarcts, cerebral venous thrombosis, or chronic lesions unrelated to the current event. Categorical data were compared using the Fisher exact test. Quantitative data were compared using the Student test or Wilcoxon test. < .05 represented a significant difference. Results Thirty men (81%) and seven women (19%) met the inclusion criteria, with a mean age of 61 years ± 12 (standard deviation) (age range, 8-78 years). The most common neurologic manifestations were alteration of consciousness (27 of 37, 73%), abnormal wakefulness when sedation was stopped (15 of 37, 41%), confusion (12 of 37, 32%), and agitation (seven of 37, 19%). The most frequent MRI findings were signal abnormalities located in the medial temporal lobe in 16 of 37 patients (43%; 95% confidence interval [CI]: 27%, 59%), nonconfluent multifocal white matter hyperintense lesions seen with fluid-attenuated inversion recovery and diffusion-weighted sequences with variable enhancement, with associated hemorrhagic lesions in 11 of 37 patients (30%; 95% CI: 15%, 45%), and extensive and isolated white matter microhemorrhages in nine of 37 patients (24%; 95% CI: 10%, 38%). A majority of patients (20 of 37, 54%) had intracerebral hemorrhagic lesions with a more severe clinical presentation and a higher admission rate in intensive care units (20 of 20 patients [100%] vs 12 of 17 patients without hemorrhage [71%], = .01) and development of the acute respiratory distress syndrome (20 of 20 patients [100%] vs 11 of 17 patients [65%], = .005). Only one patient had SARS-CoV-2 RNA in the cerebrospinal fluid. Conclusion Patients with severe coronavirus disease 2019 and without ischemic infarcts had a wide range of neurologic manifestations that were associated with abnormal brain MRI scans. Eight distinctive neuroradiologic patterns were described. © RSNA, 2020.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1148/radiol.2020202222DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301613PMC
November 2020

Guillain-Barré syndrome related to SARS-CoV-2 infection.

Authors:
Kévin Bigaut Martial Mallaret Seyyid Baloglu Benjamin Nemoz Patrice Morand Florent Baicry Alexandre Godon Paul Voulleminot Laurent Kremer Jean-Baptiste Chanson Jérôme de Seze

Neurol Neuroimmunol Neuroinflamm 2020 09 27;7(5). Epub 2020 May 27.

From the Service de Neurologie (K.B., P.V., L.K., J.-B.C., J.S.), Hôpitaux Universitaires de Strasbourg; Service de Neurologie (M.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche; Service de Neuroradiologie (S.B.), Hôpitaux Universitaires de Strasbourg; Institut de Biologie Structurale (IBS) (B.N., P.M.), Université de Grenoble Alpes, CEA, CNRS; Laboratoire de virologie (B.N., P.M.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche; Service d'Accueil des Urgences (F.B.), Hôpitaux Universitaires de Strasbourg; and Service de Réanimation Polyvalente Chirurgicale (A.G.), Centre Hospitalo-Universitaire de Grenoble Alpes, La Tronche, France.

View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1212/NXI.0000000000000785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286648PMC
September 2020

Grade III meningioma with gastro-intestinal tract and brain metastases: case report and review of the literature.

Authors:
Laura Bender Benoit Lhermitte Hélène Carinato Seyyid Baloglu Mehdi Helali Hélène Cebula Delphine Antoni Georges Noel

World J Surg Oncol 2019 Apr 16;17(1):70. Epub 2019 Apr 16.

Radiotherapy Department, Centre Paul Strauss, UNICANCER, 3, rue de la Porte de l'hôpital, F-67065, Strasbourg, France.

Background: Meningioma is the most common adult primary intracranial tumor. Malignant meningioma is a rare variant of meningioma. The prognosis for the patients with these tumors is poor, due to the tumor's capacity for relapse and to develop distant metastases. These tumors can present the same evolutionary course as aggressive carcinoma.

Case Description: We report the case of distant brain and gastro-intestinal tract (GIT) metastases. A 78-year-old patient developed malignant meningioma with a Ki-67 proliferative index of 40%. According to guidelines, surgery followed by postoperative radiotherapy (RT) was performed. Three months after the end of RT, he presented histologically proven meningioma distant brain and GIT metastases.

Conclusions: To our knowledge, this is the first case of meningioma GIT metastases. Also, we report the difficulty to confirm the diagnosis of meningioma metastases. Indeed, malignant meningioma has the same histopathological features as melanoma or carcinoma. The standard of care for the management of malignant meningioma is gross total surgery followed by postoperative radiotherapy. Metastatic meningioma is uncommon and no guidelines for the management of recurrent or metastatic meningioma have yet been published. However, several studies reported systemic therapeutic options such as antibody against VEGF, somatostatin analogs, PDGF-R, and VEGF-R tyrosine kinase inhibitors, in the case of recurrent or metastatic meningioma. We also made a review of the actual literature of systemic treatment options for metastatic meningioma.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://dx.doi.org/10.1186/s12957-019-1596-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469106PMC
April 2019

Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD).

Authors:
Kévin Bigaut Sophie Achard Céline Hemmert Seyyid Baloglu Laurent Kremer Nicolas Collongues Jérôme De Sèze Stéphane Kremer

PLoS One 2019 29;14(1):e0211465. Epub 2019 Jan 29.

Department of radiology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Background: The relation between brain functional connectivity of patients with neuromyelitis optica spectrum disorder (NMOSD) and the degree of disability remains unclear.

Objective: Compare brain functional connectivity of patients with NMOSD to healthy subjects in resting-state functional MRI (rs-fMRI).

Methods: We compared the rs-fMRI connectivity in 12 NMOSD patients with 20 healthy subjects matched for age and sex. Graph theory analysis was used to quantify the role of each node using a set of metrics: degree, global efficiency, clustering and modularity. To summarize the abnormal connectivity profile of brain regions in patients compared to healthy subjects, we defined a hub disruption index κ.

Results: Concerning the global organization of networks in NMOSD, a small-world topology was preserved without significant modification concerning all average metrics. However, visual networks and the sensorimotor network showed decreased connectivity with high interindividual variability. The hub disruption index κ was correlated to the Expanded Disability Status Scale (EDSS).

Conclusion: These results demonstrate a correlation between disability according to the EDSS and neuronal reorganization using the rs-fMRI graph methodology. The conservation of a normal global topological structure despite local modifications in functional connectivity seems to show brain plasticity in response to the disability.
View Article and Find Full Text PDF

Download full-text PDF

 Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211465PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351056PMC
November 2019